Asthma Biologics Treatment
哮喘生物制剂治疗
Duration
3-5 days for assessment and first dose
Recovery
No recovery needed; benefits develop over 4-12 weeks
Savings
~76% vs US
Average savings compared to US prices
Targeted biologic therapy for severe asthma using monoclonal antibodies including omalizumab (anti-IgE), mepolizumab (anti-IL-5), dupilumab (anti-IL-4/13), and benralizumab. China's top respiratory centers offer comprehensive asthma phenotyping and biomarker-guided biologic selection at substantially lower costs than Western countries. Treatment dramatically reduces exacerbations and steroid dependence in eligible patients with uncontrolled severe asthma.
Severe Asthma Phenotyping
Comprehensive evaluation including lung function, FeNO measurement, blood eosinophils, total IgE, allergy testing, and CT imaging
Duration: 1-2 daysBiologic Selection
Based on biomarker profile, specialist selects optimal biologic agent and discusses expected outcomes and administration schedule
Duration: 1 dayFirst Dose Administration
Subcutaneous injection administered in clinic with 1-2 hour observation period for any injection reactions
Duration: 2-3 hoursTreatment Plan & Supply
Arrangement of ongoing medication supply, training on self-injection if applicable, and steroid tapering schedule
Duration: 1 day- Biologics reduce severe exacerbations by 50-70%
- Enables oral corticosteroid dose reduction or elimination
- Chinese biosimilar and locally-manufactured biologics offer major cost savings
- Biomarker-guided selection ensures appropriate patient matching
- Injection site reactions in 5-10% of patients
- Rare anaphylactic reactions require clinic observation
- Not all patients respond to first biologic selected
- Long-term immunomodulatory effects still being studied
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.